OIVD In Brief
This article was originally published in The Gray Sheet
Executive Summary
New fees to compensate OIVD for CDER consults? Director of FDA's Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) floats the idea of sharing user fees or pursuing some other cost-sharing initiative with FDA's Center for Drug Evaluation and Research (CDER) to compensate for the expanding amount of personalized medicine-related product consults CDER is sending its way. "We are getting an increasing number of consults from CDER because of personalized medicine, which is taking an increasing amount of workload, and we get nothing from them," OIVD Director Alberto Gutierrez said at an April 22 roundtable discussion at the Association of Medical Diagnostics Manufacturers annual meeting in Bethesda, Md. "We would like some user fees or to find a way for CDER to share the wealth with us," Gutierrez said in response to a question regarding any user fee reauthorizations OIVD might be seeking. Such an arrangement could be a challenge, however, since user fee laws differ for FDA's device and drug centers and are negotiated independently
You may also be interested in...
Radiology Devices Move To OIVD: More Cohesive Dx Reviews Ahead?
FDA hopes that shuttling its Radiological Devices Branch to the Office of In Vitro Diagnostic Device Evaluation and Safety will produce more cohesive policies on diagnostic device review
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.